What should a general practicioner know about the most common cancers - Breast cancer

Abstract

Anti-HER2 treatment with pertuzumab and trastuzumab in early breast cancer reduces the risk of relapse by 1 % against trastuzumab alone at median follow-up of 45.4 months.

Keywords

• breast cancer
• chemotherapy,
• anti-HER2 treatment